Treace Medical Concepts, Inc. (TMCI) Misses Q4 EPS by 1c; offers guidance

Treace Medical Concepts, Inc. (NASDAQ: TMCI) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $62.2 million versus the consensus estimate of $60.57 million.

GUIDANCE:

Treace Medical Concepts, Inc. sees FY2024 revenue of $220-225 million, versus the consensus of $223.1 million. which represents approximately 18% to 20% growth over full-year 2023 revenue.

The Company expects to make significant progress towards Adjusted EBITDA breakeven for full-year 2024 and anticipates Adjusted EBITDA to improve approximately 50% compared to full-year 2023.

For earnings history and earnings-related data on Treace Medical Concepts, Inc. (TMCI) click here.

You May Also Be Interested In

• Elevance Health Inc. (ELV) Tops Q2 EPS by 124c, raises guidance
• Goldman Sachs Double Downgrades Blau Farmaceutica (BLAU3:BZ) to Sell
• SCHMID Group raises 2026 order intake guidance to €125-€150M